Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Inclusion Criteria: * Diagnosis of grade 1-3 follicular lymphoma with persistent, relapsed, or refractory disease to at least one prior regimen. * No prior bortezomib therapy. * Voluntary written informed consent. * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control. * Male subject agrees to use an acceptable method for contraception for the duration of the study therapy. * 18 years of age or older. * aspartate aminotransferase (AST),alanine aminotransferase (ALT), total bilirubin \< 3 times the upper limit of normal unless documented by the treating physician to be secondary to underlying lymphoma. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Exclusion Criteria: * Platelet count of \< 50,000 within 14 days before enrollment unless documented by the treating physician to be due to the disease. * Absolute neutrophil count of \< 1000 within 14 days before enrollment unless documented by the treating physician to be due to disease. * Estimated or measured creatinine clearance of less than 30 ml/min within 14 days before enrollment. * ≥Grade 2 peripheral neuropathy within 14 days before enrollment. * Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia. * Patient has hypersensitivity to boron, mannitol or any drug included in the current protocol. * Female subject is pregnant or lactating. * Received other investigational drugs for this disease within 14 days of enrollment * Serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Known HIV+ status. * Cardiac ejection fraction less than 35% at study entry measured by echocardiogram, Multigated Acquisition (MUGA) or cardiac MRI.